Aimovig (erenumab)
We can help with your prescription. Read the “Prescription Guide”.
You can access this medicine even if it's not approved in your country. Learn how.
Aimovig (erenumab) is a medication used for the treatment to help prevent migraines in adults.
Disease Indications
Migraine
Manufacturer
Amgen Inc.
Novartis Pharmaceuticals Corporation
Usage
Subcutaneous
Medicine approved by
-
European Medical Agency (EMA)
-
Food and Drug Administration (FDA)
-
Health Canada
-
Pharmaceuticals and Medical Devices Agency (PMDA)
-
Therapeutic Goods Administration (TGA)
-
Swissmedic (CH)
-
Medsafe (NZ)
Patients helped
- Over 1.2 million patients reached
- More than 11,000 patients helped
- 100% successful deliveries to 88 countries
We can help with your import documents
We are experts in import regulations. Scroll below to download the import guide for your country.
FREQUENTLY ASKED QUESTIONS
We help you access approved medicines that are not approved or available in your country of residence.
Legal
Finances
Payment
- Your permanent residence is outside the European Union
- You take the medicines with you, unused within 90 days after purchase
- You have a full original receipt (which we provide you)
Unfortunately, we are unable to help with VAT refunds following delivery or collection from our partner pharmacies outside of the Netherlands.
- If you are residing within the European Union and you are not a company
- If you are coming to Amsterdam, Luxembourg or Dusseldorf to pick up your order
In case of pick up, you may be eligible for a VAT tax refund if you live outside the European Union.
Price
Reimbursement
- That you want to import an approved medicine from abroad
- The lack of reasonable treatment options available in your country (if you can, include a letter from a doctor confirming this) - no alternative to the treatment.
- That the medicine has already been approved in another country (state the name of the country)
- That your treating doctor states that this medicine is the best option for you (include a copy of the prescription in the letter to the healthcare insurance company)
Ordering and shipping
Ordering
- Name of the patient
- Contact details of patient(email and phone number)
- Copy of patient’s ID
- Contact details of the Doctor (name, address, email and phone number)
- Shipping address
- Copy of the doctor's prescription
Shipping: We can deliver to the patient's residence, a pharmacy, or doctor's office / hospital, but this depends on the country. If you’re not sure what the right choice is for you, please get in touch with our Patient Support Team and we can help you work out your exact requirements.
Once we have received this information, one of our Patient Support Team members will then check your prescription and contact you to follow up on your order. Please note that other documents may be needed for import, we will guide you through the ordering process.
Generally not, but we do provide you with an invoice after you make the payment that you may send to your medical insurance company so they can reimburse you. In some limited circumstances, we do accept insurance. Contact us for more details.
As part of our protocols we might reach out to your treating doctor for verification or information updates. By sending us your prescription you allow us to do so.
- Patient's name and date of birth
- Name of the medicine and dosage
- Required quantity
- Doctor's name and signature
- Doctor's registration number and/or stamp
Ideally, the prescription should be issued in English. Alternatively, a translation (unofficial is sufficient) must be provided.
Please be aware that your doctor may be contacted by one of our team members or by the processing pharmacy in order to verify the prescription.
Shipping
Please be aware that due to the COVID-19 situation worldwide and the country lockdowns, we will sometimes experience delays in shipping.
For EMA approved medicines with prescriptions from within the Schengen zone, you can pick the medicines up from our partner pharmacy in Amsterdam, Luxembourg or Dusseldorf. For non-EMA approved medicines, with prescriptions from within the Schengen zone, you can pick the medicines up in our partner pharmacy in Dusseldorf. If you have requested to collect your medicines, you will receive a notification when the medicines are in the pharmacy and ready for you.
There are also options to deliver the medicines to other countries. Please get in touch with our Patient Support Team to discuss which other pick-up and delivery options may be suitable for you.
- Copy of the ID/passport of the patient
- Copy of the ID/passport of the person who is coming to pick up the medicines
- Letter signed by the patient stating that he/she authorises this person to pick up the medicines on his/her behalf
- Step 1 - Customs may need to check the package to verify its contents. In order to streamline this step, we include a letter for customs with information about the contents. Any additional questions will be answered by TheSocialMedwork as and when we are contacted by customs.
- Step 2 - In some countries, there are additional questions from the medical regulatory agencies (i.e. the FDA, EMA, etc). We provide them with all the necessary information based on the information provided by the patient, such as: the prescription, copy of ID and a letter from the treating doctor to show that the medicines are for personal use.
- Step 3 - Customs fees. In some cases, the recipient will be requested to pay taxes and duties. These should be arranged by the patient or receiver and are not covered by TheSocialMedwork unless stated otherwise.
Please be aware that the import of the medicines always requires customs clearance and active cooperation from the importing party. We will help and guide you but are dependent on your cooperation and responsiveness.
About us
- Complete the enquiry form on our Contact Us page
- Send an email: [email protected]
- Call us on:
- +31 20 808 4414 (EU)
- +1 646 381 0675 (US)
- +61 28 417 2910 (AUS)
Others
Available medicines
Medicine approval
The respective national and regional agencies, such as the Food and Drugs Administration (FDA) in the USA or the European Medical Authority (EMA) for the European Union assess these applications and make a decision on whether to approve new medicines. The review process is based on evaluation of the evidence provided by the company. Every agency uses a slightly different process.
- Phase I - performed in a small number of healthy volunteers or very sick patients with lack of treatment options, designed to study the effects of the medicine in the human body.
- Phase II - larger number of patients, designed to evaluate the safety and efficacy of the medicine and to determine if different dosages of the treatment have different effects.
- Phase III - large number of patient groups, designed to confirm the safety and efficacy of the medicine.
- Phase IV - after the medicine has received regulatory approval, designed to evaluate the long-term effects.
Updates
Aimovig (erenumab)
Package
SureClick Autoinjector
Where can we deliver?
We have delivered medicines to more than 88 countries. Check if we have sent medicines to yours.
We currently can’t ship medicines to - contact us for alternative options.
Make an enquiry to receive information about the different options of obtaining for a patient in .
We haven’t shipped medicines to yet. You can count on us to make it happen.
Make an enquiry to receive information about the cost, shipping time and import details for .
Yes, we have successfully delivered medicines to .
Make an enquiry to receive information about the cost, shipping time and import details for .
PICK-UP IN PERSON FROM A PARTNER PHARMACY
We can arrange for you to pick up this medicine from our partner pharmacy in Luxembourg. Read more.
Pick-up from Luxembourg.
Depending on your particular circumstance, this option can be cheaper and require less paperwork than direct delivery. You can ask someone else to pick up the medicine on your behalf.
In some cases, medicines can be picked up from partner pharmacies in Amsterdam (the Netherlands) or Dusseldorf (Germany).
Tell our Patient Support Team if you’re interested in pick-up options for your order.
Our Patient Support Team will personally assist you along the way
Dr. Akshi Sudan
Patient Support Team Lead
Daniela Figueira, PharmaD
Patient Support Agent
Registered independent intermediary. View certificate.
GDP compliant. View certificate.
Licensed wholesale distributor. View certificate.
What is Aimovig (erenumab)?
Aimovig (erenumab) is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks1.
It is available as an AutoInjector pen containing 70mg/ml or 140mg/ml
Who is Aimovig (erenumab) for?
Aimovig (erenumab) is indicated for use as once monthly preventive treatment for adults who suffer from migraines. This includes migraine subtypes: episodic and chronic that are defined respectively as 4 to 14 migraine days per month (episodic) and 15 or more headaches per month of which 8 are migraine days (chronic)2. [Please note that approvals in some countries may be for some subtypes and not all migraines].
How does Aimovig (erenumab) work?
The active substance in Aimovig, erenumab, is a human monoclonal antibody that blocks the activity of a molecule called calcitonin gene-related peptide (CGRP) which is involved in migraine attacks1,2.
Although the exact causes of migraine are still unknown, multiple studies have confirmed that the release of calcitonin gene-related peptide (CGRP) is increased during acute migraine attacks. The inhibition of CGRP and its receptor has proved effective in migraine pain relief, supporting the hypothesis of its involvement in the disease3.
Where has Aimovig (erenumab) been approved?
Aimovig (erenumab) was approved for the treatment of patients with migraine by:
- Food and Drug Administration (FDA), USA, on May 17, 20181
- Therapeutic Goods Administration (TGA), Australia, July 2, 20184
- Swissmedic, Switzerland, July 13, 20186
- European Medical Agency (EMA), European Union, July 26, 2018, indicated for the treatment in adults with 4 or more migraine days per month5
- Health Canada, Canada, August 1, 2018, indicated for the treatment in adults with 4 or more migraine days per month7
- Medsafe, New Zealand, January 16, 2020.8
- The Pharmaceuticals and Medical Devices Agency (PMDA), Japan on June 23, 2021
Please note that this prescription medication may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval and availability in a specific country feel free to contact our support team for assistance.
We have supported patients from various countries access Aimovig. The majority of our patients who have requested access to this medicine come from:
- United Kingdom (UK)
- Portugal
- Turkey
- Egypt
- Pakistan
- Romania
- South Africa
How is Aimovig (erenumab) taken?
The standard dosage is2:
-
70 mg injected subcutaneously (under the skin) once monthly.
-
Some patients may benefit from a dosage of 140 mg injected subcutaneously once monthly, which is administered as two consecutive subcutaneous injections of 70 mg each.
Aimovig (erenumab) is intended for patient self-administration.
Complete information about Aimovig (erenumab) dosage and administration can be found in the official prescribing information listed in our resources section2.
Note: To be sure how much medicine you need to dose per month, please consult with your treating doctor for personalised dosing.
Are there any known side effects or adverse reactions of Aimovig (erenumab)?
Common adverse reactions
The most common adverse reactions occurring with a frequency of at least 3% listed in the prescribing information include2:
-
injection site reactions
-
constipation.
Contraindications
Aimovig (erenumab-aooe) is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients2.Use in specific populations
Women with migraine may be concerned about getting pregnant and breastfeeding due to fears of exposing the baby to medication.There are no adequate data yet on the developmental risk associated with the use of Aimovig (erenumab) on pregnancy and breastfeeding.2
For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information2.
Please note that Amovig or Aimoving are common misspellings of Amovig. These are not different medicines.
Reference
1. FDA News Release: FDA approves novel preventive treatment for migraine www.fda.gov, May 2018.
2. Summary of Product Characteristics [FDA]: Aimovig (erenumab-aooe) [PDF], Amgen, March 2019 (revised).
3. CGRP as the target of new migraine therapies, Edvinsson L. et al. Nature Reviews Neurology. 24/04/2018; volume 14: 338–350.
4. TGA Public Summary: Aimovig (erenumab) [PDF], Novartis, October 29, 2019 (revised).
5. Summary of Product Characteristics [EMA]: Aimovig (erenumab) [PDF], Novartis Europharm, July 2018.
6. Summary of the Risk Management Plan (RMP) for Aimovig (erenumab) [PDF], Novartis, September 2018.
7. Product Monograph (Health Canada): Aimovig (erenumab) [PDF], Novartis, November 2019 (revised).
8. New Zealand Data Sheet (Medsafe): AIMOVIGTM (erenumab) [PDF], Novartis, January 2020.
The Food and Drug Administration (FDA), USA, approval of Aimovig (erenumab) for migraine as a preventive treatment of episodic or chronic migraine was evaluated in three randomized, double-blind, placebo-controlled studies: two studies in patients with episodic migraine (Study 1 and Study 2) and one study in patients with chronic migraine (Study 3)1.
Migraine is considered episodic when it occurs over 4 to 14 days per month. Chronic migraine is characterised by more than 15 headache days per month of which more than 8 are migraine days. The studies enrolled patients with a history of migraine, with or without aura, according to the International Classification of Headache Disorders (ICHD-III) diagnostic criteria1.
Episodic migraine
Study 1 (NCT 02456740) was a randomized, multi-center, 6-month, placebo-controlled, double-blind study. This study involved a total of 955 patients with a history of episodic migraine who were randomly assigned to one of 3 groups: Aimovig 70 mg (N = 317), Aimovig 140 mg (N = 319), or placebo (N = 319) by subcutaneous injection once monthly for 6 months. Patients were allowed to use acute headache treatments including migraine-specific medication1.
Study 2 (NCT 02483585) was a randomized, multi-center, 3-month, placebo-controlled, double-blind study. A total of 577 patients with a history of episodic migraine were randomly assigned to one of 2 groups: Aimovig 70 mg (N = 286) or placebo (N = 291) by subcutaneous injection once monthly for 3 months. Patients were allowed to use acute headache treatments including migraine-specific medication1.
Results
Among the efficacy outcome measures were
-
the change from the beginning of the study in the mean number of migraine days per month over months 4 to 6 (MMD)
-
the achievement of a ≥ 50% reduction at the beginning of the study in the mean number of migraine days per month over months 4 to 6 (≥ 50% MMD responders)
-
the change from the beginning of the study in the mean number of days per month in which acute migraine-specific medication was needed over months 4 to 6.
The change in MMD was1:
-
-3.2 with Aimovig 70mg in Study 1
-
Difference from placebo: -1.4
-
-2.9 with Aimovig 70mg in Study 2
-
Difference from placebo: -1.0
-
-3.7 with Aimovig 140mg in Study 1
-
Difference from placebo: -1.9.
The ≥ 50% MMD responders were1:
-
43.3% with Aimovig 70mg in Study 1
-
Difference from placebo: 16.7%
-
39.7% with Aimovig 70mg in Study 2
-
Difference from placebo: 10.2%
-
50% with Aimovig 140mg in Study 1
-
Difference from placebo: 23.4%.
The change in number of days when acute medication was needed was1:
-
-1.1 with Aimovig 70mg in Study 1
-
Difference from placebo: -0.9
-
-1.2 with Aimovig 70mg in Study 2
-
Difference from placebo: -0.6
-
-1.6 with Aimovig 140mg in Study 1
-
Difference from placebo: -1.4.
Chronic migraine
Study 3 (NCT 02066415) was a randomized, multi-center, 3-month, placebo-controlled, double-blind study. A total of 667 patients with a history of chronic migraine with or without aura were randomly assigned to one of 3 groups: Aimovig 70 mg (N = 191), Aimovig 140 mg (N = 190), or placebo (N = 286) by subcutaneous injections once monthly for 3 months. Patients were allowed to use acute headache treatments including migraine-specific medication1.
Results
Among the efficacy outcome measures were
-
the change from the beginning of the study in the mean number of migraine days per month over months 4 to 6 (MMD)
-
the achievement of a ≥ 50% reduction at the beginning of the study in the mean number of migraine days per month over months 4 to 6 (≥ 50% MMD responders)
-
the change from the beginning of the study in the mean number of days per month in which acute migraine-specific medication was needed over months 4 to 6.
The change in MMD was1:
-
-6.6 with Aimovig 70mg in Study 3
-
Difference from placebo: -2.5
-
-6.6 with Aimovig 140mg in Study 3
-
Difference from placebo: -2.5.
The ≥ 50% MMD responders were1:
-
39.9% with Aimovig 70mg in Study 3
-
Difference from placebo: 16.4%
-
41.2% with Aimovig 140mg in Study 3
-
Difference from placebo: 17.7%.
The change in number of days when acute medication was needed was1:
-
-3.5 with Aimovig 70mg in Study 3
-
Difference from placebo: -1.9
-
-4.1 with Aimovig 140mg in Study 3
-
Difference from placebo: -2.6.
Reference
1. Summary of Product Characteristics [FDA]: Aimovig (erenumab-aooe) [PDF], Amgen, March 2019 (revised).
Aimovig (erenumab) price in other currencies*
| Package | Euro | Turkish lira |
|---|---|---|
| 1 Autoinjector(s) of 70mg/ml | 561 EUR | 9773 TRY |
| 3 Autoinjector(s) of 70mg/ml | 1360 EUR | 23690 TRY |
| 1 Autoinjector(s) of 140mg/ml | 561 EUR | 9773 TRY |
| 3 Autoinjector(s) of 140mg/ml | 1406 EUR | 24483 TRY |
*The prices listed above are based on the cheapest package size and strength TheSocialMedwork has access to. Please make an enquiry for more specific pricing. The prices listed above are a guide only, we operate in Euros.
Aimovig (erenumab) treatment costs
The cost for a monthly or yearly treatment of Aimovig (erenumab) depends on your prescription requirements which includes the dosage in mg/ml and medicine type (SureClick Autoinjector).
The price of the medicines you see on sale is the cost set by the manufacturer. In addition, shipping costs and a Named Patient support fee will apply.
Make an enquiry and we will help you calculate the total price to buy Aimovig (erenumab) online and have it delivered where you live. From your side, we’ll simply need a prescription from your treating doctor. In some countries we might also need an import license. Our Patient Support team will guide you throughout the process.
Aimovig (erenumab) price and additional costs
The price of Aimovig (erenumab)
The base cost of each medicine is set by the manufacturer. Generally, our Named Patient support fee, shipping costs and any local tax (if applicable) are not included in the product price that is displayed on our website unless stated otherwise.
Our Named Patient support fee
TheSocialMedwork provides access to Aimovig (erenumab) on the Named Patient import basis, which means that we work on behalf of the patient in cooperation with their treating doctor. Our Named Patient support fee covers sourcing, logistics and following up to make sure that the order is received safely and in perfect condition. The Named Patient support fee is tiered relative to the cost of the medicine.
Shipping costs
The shipping prices are dependent on the type of shipping necessary for the particular medicine (regular or cold chain) and upon the destination country. The shipping fees may include the shipping from our supplier to our partner pharmacy as well as the shipping costs to deliver the medicine to the patient’s country of residence. The shipping fee might also include the cost of special packaging, such as coolboxes, cool packs and data loggers, as well as transport insurance to guarantee that you receive your medicine in good order.
You can read a detailed overview of prices and costs here.
Payment methods when you buy Aimovig (erenumab)
When you buy Aimovig (erenumab), you can make the payment by bank transfer or by credit card. Payments are fully encrypted and secure. When paying by credit card, you can pay online once you have received your order confirmation. Please be aware that a 2.8% fee applies when paying by credit card.
Aimovig (erenumab) reimbursement
It might be possible for you to claim the cost of Aimovig (erenumab) via your country's healthcare system. Some countries have a government fund providing financial assistance for citizens to access lifesaving medical treatment abroad. The best thing would be to check with your country's own health ministry. We also highly recommend checking out local patient blogs, communities and patient organisations to find out more about your options.
Medical insurance
Generally, we do not support medical insurance, but we do provide you with an invoice after you make the payment that you may send to your medical insurance company so they can reimburse you. In some limited circumstances, we do accept insurance. Contact us for more details. You can pay by bank transfer or credit card.
Crowdfunding
Crowdfunding might also be an option for you. It is a means of raising funds by using an online platform to group together many small donations from friends, family and others, in order to help you afford medical treatment. Here are some crowdfunding platforms where you can seek support: GoFundMe, GiveForward, FundRazr and Watsi.
Cold chain shipping
Some medicinal ingredients are susceptible to damage from heat, light and handling. Using "cold chain" delivery, specialised medical couriers have temperature regulated boxes and vehicles to ensure that the medicine is uncompromised. For that reason, cold chain shipping can be more expensive than regular shipping. For more details, please see our article on cold chain delivery.
Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised cold chain couriers. If you would like your order to be shipped by a specific courier, please inform us when you place the order.
Our standard delivery time varies from 5 to 10 working days.
The shipping cost depends on the medicine and the destination country. After making an enquiry, you will receive a detailed quote that includes the shipping costs.
You can also pick up your medicine from our partner pharmacy in Amsterdam or our partner pharmacy in Luxembourg after the order has been paid for.
Four steps to access the medicines you need
How and where to access and buy Aimovig: You can access Aimovig from TheSocialMedwork if the drug has not been approved or is not available in your country.
-
Step 1
You send a request for your medicine online
Submit a request for a specific medicine, or a general request, and your Patient Support Manager will contact you within 24 hours. They will be there to support and guide you in anyway possible to help you get the medicine you need.
-
Step 2
We verify your prescription and medical details
Since we help patients access medicines not available in their home country, our first step is to check that the medicine you need is not currently available in your home country. Next we will also verify that you have a prescription from a doctor in your home country for the medicine you need.
-
Step 3
We source your medicine
Once we have verified your prescription and medical details, our expert sourcing team will work with our global network of suppliers to find you the best price. Once we have found you the lowest possible cost for your medicine, we will present you with a final offer for your approval.
-
Step 4
We deliver your medicine
After you have accepted our offer, our experienced logistics team will arrange all the shipping and transportation of your medicine. We will work hard to keep you informed at every step along the way and get your medicine to you quickly and safely. To date we have successfully delivered packages to over 75 countries around the world.
Our patients share their stories
Read morePatient reviews
“I want to recommend everyone to work with this organization. They are reliable, honest, punctual and do everything to meet your needs…”
“Dr. Aysen Simsek and her team offered assistance during a very difficult time. I truly appreciate their quick, efficient and professional attitude, as well as their patience and superb customer service…”
“I highly recommend TheSocialMedwork. They welcomed me with open arms when I went to their office in Amsterdam. I was in a very difficult situation with a tight schedule, and their amazing team members…”
We are highly rated by our patients
Looking for more information? Download your free guide on: “How to import a medicine”.
Select your preferred country and input your email to receive a step by step guide on how we can help you legally and safely import a medicine that is not approved in your country.
Thank you!
You will receive an email with a download link to your guide (or a confirmation if you selected Other) at [email protected]. Please check your spam or junk folder.
Back to pageContact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 18:00 CET.
Call
+31 20 808 4414About us
We are TheSocialMedwork, a registered medical intermediary that helps you access elsewhere approved medicines, no matter where you live. To date, we have assisted patients in over 88 countries to access thousands of life-improving medicines.
Learn moreAbout us
Disclaimer
Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.
